Wolfram Doehner
Research Subjects
Research Interests
Wolfram Doehner has a total of 41 co-authors. Here are the top co-authors by number of shared publications:
Stefan D. Anker
Department of Clinical Cardiology, National Heart & Lung Institute, Imperial College School of Medicine, London, UK
3 shared publicationsA. Sandek
Charite - Campus Virchow-Klinikum, Department of Cardiology, Division of Applied Cachexia Research, Berlin, Germany
2 shared publications- Andrew Justin Stewart Coats
Heart Research Institute, University of Sydney , 7 Eliza St, Newtown, Sydney, NSW 2042
2 shared publications Mathias Rauchhaus
2 shared publicationsRakesh Sharma
2 shared publicationsStefan D Anker
2 shared publications
Latest Publications
- Open Access
- 1 August 2013
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 34 (suppl 1) , P5077
C-terminal agrin-fragment as a novel diagnostic marker for muscle wasting in patients with chronic heart failure: results from the studies investigating co-morbidities aggravating heart failure
Aims: Skeletal muscle wasting affects about 20% of patients with chronic heart failure (CHF) and has significant implications for patients' exercise capacity. The accurate assessment of muscle wasting is technically challenging. Agrin is a synaptically located protein which is responsible for initial formation and maintenance of neuromuscular junctions. C-terminal agrin-fragment (CAF) is a proteolytic breakdown product of agrin that has recently been suggested as a candidate marker for the detection of muscle wasting. Methods and results: We assessed serum CAF in 197 CHF patients who participated in the Studies Investigating Co-morbidities Aggravating Heart Failure (SICA-HF, age 67±10 years, New York Heart Association [NYHA] class I/II/III/IV 7/55/38/2%, median CAF 98 pmol/L with interquartile range [IQR] 77-123 pM, median LVEF 35% with IQR 30-53%). Muscle wasting was identified using dual-energy X-ray absorptiometry (DEXA) as defined by international standards in n=38 (19.3%). Fifty-five CHF patients showed CAF values above the upper reference limit of 120 pmol/L. CHF patients with muscle wasting demonstrated higher CAF values than CHF patients without muscle wasting (125.1±59.5 vs. 103.2±45.5 pmol/L, p=0.01). Using Receiver Operator Characteristic (ROC) curve analysis, we calculated the optimal CAF value to correctly identify patients with muscle wasting as >87.5 pmol/L, which had a sensitivity of 78.9% and a specificity of 44.0%. The area under the ROC curve was 0.64 (95% confidence interval 0.56-0.70). Using simple regression, we found that serum CAF was associated with handgrip (R=-0.17, p=0.02) and quadriceps strength (R=-0.26, p=0.0002), peak oxygen consumption (R=-0.4, pConclsusion: Serum values of CAF may be useful to identify patients with CHF and muscle wasting. Whilst its sensitivity is high, its specificity remains poor, but elevated levels should prompt further investigation using DEXA scan.
- 1 August 2013
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 34 (suppl 1) , P5077
Open AccessC-terminal agrin-fragment as a novel diagnostic marker for muscle wasting in patients with chronic heart failure: results from the studies investigating co-morbidities aggravating heart failure
Aims: Skeletal muscle wasting affects about 20% of patients with chronic heart failure (CHF) and has significant implications for patients' exercise capacity. The accurate assessment of muscle wasting is technically challenging. Agrin is a synaptically located protein which is responsible for initial formation and maintenance of neuromuscular junctions. C-terminal agrin-fragment (CAF) is a proteolytic breakdown product of agrin that has recently been suggested as a candidate marker for the detection of muscle wasting. Methods and results: We assessed serum CAF in 197 CHF patients who participated in the Studies Investigating Co-morbidities Aggravating Heart Failure (SICA-HF, age 67±10 years, New York Heart Association [NYHA] class I/II/III/IV 7/55/38/2%, median CAF 98 pmol/L with interquartile range [IQR] 77-123 pM, median LVEF 35% with IQR 30-53%). Muscle wasting was identified using dual-energy X-ray absorptiometry (DEXA) as defined by international standards in n=38 (19.3%). Fifty-five CHF patients showed CAF values above the upper reference limit of 120 pmol/L. CHF patients with muscle wasting demonstrated higher CAF values than CHF patients without muscle wasting (125.1±59.5 vs. 103.2±45.5 pmol/L, p=0.01). Using Receiver Operator Characteristic (ROC) curve analysis, we calculated the optimal CAF value to correctly identify patients with muscle wasting as >87.5 pmol/L, which had a sensitivity of 78.9% and a specificity of 44.0%. The area under the ROC curve was 0.64 (95% confidence interval 0.56-0.70). Using simple regression, we found that serum CAF was associated with handgrip (R=-0.17, p=0.02) and quadriceps strength (R=-0.26, p=0.0002), peak oxygen consumption (R=-0.4, pConclsusion: Serum values of CAF may be useful to identify patients with CHF and muscle wasting. Whilst its sensitivity is high, its specificity remains poor, but elevated levels should prompt further investigation using DEXA scan.
- 24 May 2006
- Published by Georg Thieme Verlag KG in Aktuelle Ernahrungsmedizin
- Vol. 31 (03) , P1_9
Exercise limitation in pancreatic cancer: the potential impact of changes in body composition (cachexia)
Background: In cancer, reduced exercise capacity is frequently seen, its origin is unclear. Metabolic abnormalities within the skeletal muscle, independent of left ventricular (LV) function may contribute to exercise limitation. The objective of the study was to investigate potential mechanisms for exercise limitation in patients with pancreatic cancer (PCA). Methods: We examined 25 patients with PCA (age 61+/-11 years, mean +/- SD, Karnofsky index 85+/-10%, time since diagnosis 281+/-222 days). Exercise capacity (treadmill, RQ 1.1+/-0.1 vs. 1.2+/-0.1), LV systolic and diastolic function (echo), body composition (DEXA-scan) and limb muscle blood flow were assessed. 12 healthy subjects served as controls (age 58+/-7 years). Results: LV ejection fraction (LVEF) was not different between controls (62+/-5%) and PCA (60+/-8%, p=0.4) as was LVEDD (46+/-6 vs. 49+/-7mm, p=0.3). Diastolic function showed no differences between controls and PCA (9+/-4 vs. 8+/-4, p=0,6), nor did e' alone (0,1+/-0,03 m/s vs. 0,1+/-0,3 m/s, p=0,3) or e'/a' (0.9+/-0.2 vs. 1.1+/-0.7, p=0.5). BMI (25+/-5 vs. 22+/-3kg/m2, p=0.02) was reduced in PCA. Mean weight loss in PCA was 14±5kg. Patients with PCA had similar total lean tissue (48+/-11 vs. 51+/-10kg, p=0.5) but lower fat tissue mass (13+/-5 vs. 22+/-10kg, p=0.0006) and fat tissue content (20+/-7 vs. 31+/-10%, p=0.0004). Exercise capacity (peak VO2 20+/-6 vs. 26+/-6 mL/min/kg, p=0.008) and AT (13+/-2 vs. 15+/-4 mL/min/kg, p=0.03) were reduced in PCA, although the VE/VCO2-slope was similar (35+/-9 vs. 29+/-6, p=0.1). In controls, total peak VO2 related to total lean tissue (r=0.9, pConclusion: Exercise capacity is impaired in PCA, independent of lean tissue mass, systolic and diastolic function, ventilatory efficiency and muscle blood flow. We hypothesise according to the muscle hypothesis in CHF that symptom generation and exercise intolerance in cancer patients may be due to intrinsic metabolic changes within the skeletal muscle.
- 24 May 2006
- Published by Georg Thieme Verlag KG in Aktuelle Ernahrungsmedizin
- Vol. 31 (03) , P1_9
Exercise limitation in pancreatic cancer: the potential impact of changes in body composition (cachexia)
Background: In cancer, reduced exercise capacity is frequently seen, its origin is unclear. Metabolic abnormalities within the skeletal muscle, independent of left ventricular (LV) function may contribute to exercise limitation. The objective of the study was to investigate potential mechanisms for exercise limitation in patients with pancreatic cancer (PCA). Methods: We examined 25 patients with PCA (age 61+/-11 years, mean +/- SD, Karnofsky index 85+/-10%, time since diagnosis 281+/-222 days). Exercise capacity (treadmill, RQ 1.1+/-0.1 vs. 1.2+/-0.1), LV systolic and diastolic function (echo), body composition (DEXA-scan) and limb muscle blood flow were assessed. 12 healthy subjects served as controls (age 58+/-7 years). Results: LV ejection fraction (LVEF) was not different between controls (62+/-5%) and PCA (60+/-8%, p=0.4) as was LVEDD (46+/-6 vs. 49+/-7mm, p=0.3). Diastolic function showed no differences between controls and PCA (9+/-4 vs. 8+/-4, p=0,6), nor did e' alone (0,1+/-0,03 m/s vs. 0,1+/-0,3 m/s, p=0,3) or e'/a' (0.9+/-0.2 vs. 1.1+/-0.7, p=0.5). BMI (25+/-5 vs. 22+/-3kg/m2, p=0.02) was reduced in PCA. Mean weight loss in PCA was 14±5kg. Patients with PCA had similar total lean tissue (48+/-11 vs. 51+/-10kg, p=0.5) but lower fat tissue mass (13+/-5 vs. 22+/-10kg, p=0.0006) and fat tissue content (20+/-7 vs. 31+/-10%, p=0.0004). Exercise capacity (peak VO2 20+/-6 vs. 26+/-6 mL/min/kg, p=0.008) and AT (13+/-2 vs. 15+/-4 mL/min/kg, p=0.03) were reduced in PCA, although the VE/VCO2-slope was similar (35+/-9 vs. 29+/-6, p=0.1). In controls, total peak VO2 related to total lean tissue (r=0.9, pConclusion: Exercise capacity is impaired in PCA, independent of lean tissue mass, systolic and diastolic function, ventilatory efficiency and muscle blood flow. We hypothesise according to the muscle hypothesis in CHF that symptom generation and exercise intolerance in cancer patients may be due to intrinsic metabolic changes within the skeletal muscle.
- 1 July 2003
- p. S103-7
Anemia in chronic heart failure--frequency and prognostic impact.
Chronic heart failure (CHF) is an important public health care problem and a leading cause of morbidity and mortality world wide. Anemia is a common finding in CHF and known to cause heart failure. Patients with CHF are limited by exercise capacity and fatigue. A low hemoglobin concentration leads to impairment of both. With increasing severity of heart failure, anemia also becomes more frequent and clinically more relevant. There are many potential reasons for development of anemia in chronic heart failure like bone marrow depression, reduced intestinal iron uptake, and the dilution in consequence of sodium and water retention. However, the anemia seen in CHF is generally an "anemia of chronic illness". Furthermore, it has been shown that hemoglobin levels independently predict increased mortality in CHF.
- 1 July 2003
- p. S103-7
Anemia in chronic heart failure--frequency and prognostic impact.
Chronic heart failure (CHF) is an important public health care problem and a leading cause of morbidity and mortality world wide. Anemia is a common finding in CHF and known to cause heart failure. Patients with CHF are limited by exercise capacity and fatigue. A low hemoglobin concentration leads to impairment of both. With increasing severity of heart failure, anemia also becomes more frequent and clinically more relevant. There are many potential reasons for development of anemia in chronic heart failure like bone marrow depression, reduced intestinal iron uptake, and the dilution in consequence of sodium and water retention. However, the anemia seen in CHF is generally an "anemia of chronic illness". Furthermore, it has been shown that hemoglobin levels independently predict increased mortality in CHF.
- 1 September 2002
- Published by Elsevier in International Journal of Cardiology
- Vol. 85 (1) , 7-14
Cardiac cachexia in early literature: a review of research prior to Medline
- 1 September 2002
- Published by Elsevier in International Journal of Cardiology
- Vol. 85 (1) , 7-14
Cardiac cachexia in early literature: a review of research prior to Medline
- 1 May 2002
- Published by Elsevier in International Journal of Cardiology
- Vol. 83 (2) , 99-102
PRESTO (a mammoth trial that could have been prevented), HPS and REMATCH
- 1 May 2002
- Published by Elsevier in International Journal of Cardiology
- Vol. 83 (2) , 99-102
PRESTO (a mammoth trial that could have been prevented), HPS and REMATCH
- 1 April 2002
- Published by Elsevier in International Journal of Cardiology
- Vol. 83 (1) , 73-81
Insulin resistance in moderate chronic heart failure is related to hyperleptinaemia, but not to norepinephrine or TNF-alpha
- 1 April 2002
- Published by Elsevier in International Journal of Cardiology
- Vol. 83 (1) , 73-81
Insulin resistance in moderate chronic heart failure is related to hyperleptinaemia, but not to norepinephrine or TNF-alpha
- 1 December 2001
- Published by Oxford University Press (OUP) in European Journal of Endocrinology
- Vol. 145 (6) , 727-735
Leptin, insulin sensitivity and growth hormone binding protein in chronic heart failure with and without cardiac cachexia
OBJECTIVE: Regulation of growth hormone (GH) receptor expression and hence tissue GH sensitivity may be important for the conflicting results found in treatment studies with recombinant growth hormone in chronic heart failure (CHF). Growth hormone-binding protein (GHBP) corresponds to the extracellular domain of the GH receptor and is closely related to measures of body composition and, specifically, to size of visceral fat tissue. Leptin, the adipocyte specific (ob) gene product, has been proposed as the signal linking adipose tissue and GHBP/GH-receptor expression. CHF has recently been shown to be a hyperleptinaemic and insulin-resistant state regardless of aetiology. This study aimed to examine the influence of leptin on GHBP in CHF patients with and without cardiac cachexia compared with healthy control subjects. METHODS: We studied 47 male patients with CHF (mean age 61+/-2 years, New York Heart Association (NYHA)-class 2.7+/-0.1, left ventricular ejection fraction (LVEF) 28+/-2%, peak oxygen consumption 16.8+/-0.9 ml/kg/min) and 21 male healthy controls of similar age. Of the CHF patients, 19 were cachectic (cCHF; non-oedematous weight loss >7.5% over at least 6 months) and 28 non-cachectic (ncCHF; similar for age and LVEF). Insulin sensitivity was assessed by an intravenous glucose tolerance test using the minimal model approach. RESULTS: Compared with healthy controls, patients had elevated levels of leptin (7.6+/-0.7 vs 4.8+/-0.7 ng/ml, P<0.05), insulin (76.2+/-8.9 vs 41.4+/-6.0 pmol/l, P<0.01), and reduced insulin sensitivity (2.43+/-0.2 vs 3.48+/-0.3 min(-1).microU.ml(-1).10(4), P0.5). After correction for total body fat mass, both ncCHF and cCHF were hyperleptinaemic (41.8+/-3.8 and 37.9+/-0.38 vs 24.4+/-2.1 ng/ml/100 g, ANOVA P=0.001). In both patients and controls there was a direct correlation between leptin levels and GHBP (r=0.70 and r=0.71 respectively, both P<0.0001). This relationship was stronger than between GHBP and several parameters of body composition (body mass index (BMI), total and regional body fat mass or % body fat) and held true when sub-groups were tested individually (ncCHF r=0.62, P<0.001; cCHF r=0.79, P<0.0001). In multivariate regression analysis in all CHF patients, serum leptin levels emerged as the strongest predictor of GHBP, independent of age, BMI, total and regional fat mass or % body fat, fasting insulin level and insulin sensitivity. CONCLUSION: Fat mass corrected leptin levels are elevated in CHF patients with and without cachexia. Reduced total fat mass may account for lower leptin levels in cachectic CHF patients compared with non cachectic patients. Leptin strongly predicts GHBP levels in CHF regardless of its hyperleptinaemic state or severely altered body composition as in cardiac cachexia. Leptin could be the signalling link between adipose tissue and GHBP/GH receptor expression in CHF.
- 1 December 2001
- Published by Oxford University Press (OUP) in European Journal of Endocrinology
- Vol. 145 (6) , 727-735
Leptin, insulin sensitivity and growth hormone binding protein in chronic heart failure with and without cardiac cachexia
OBJECTIVE: Regulation of growth hormone (GH) receptor expression and hence tissue GH sensitivity may be important for the conflicting results found in treatment studies with recombinant growth hormone in chronic heart failure (CHF). Growth hormone-binding protein (GHBP) corresponds to the extracellular domain of the GH receptor and is closely related to measures of body composition and, specifically, to size of visceral fat tissue. Leptin, the adipocyte specific (ob) gene product, has been proposed as the signal linking adipose tissue and GHBP/GH-receptor expression. CHF has recently been shown to be a hyperleptinaemic and insulin-resistant state regardless of aetiology. This study aimed to examine the influence of leptin on GHBP in CHF patients with and without cardiac cachexia compared with healthy control subjects. METHODS: We studied 47 male patients with CHF (mean age 61+/-2 years, New York Heart Association (NYHA)-class 2.7+/-0.1, left ventricular ejection fraction (LVEF) 28+/-2%, peak oxygen consumption 16.8+/-0.9 ml/kg/min) and 21 male healthy controls of similar age. Of the CHF patients, 19 were cachectic (cCHF; non-oedematous weight loss >7.5% over at least 6 months) and 28 non-cachectic (ncCHF; similar for age and LVEF). Insulin sensitivity was assessed by an intravenous glucose tolerance test using the minimal model approach. RESULTS: Compared with healthy controls, patients had elevated levels of leptin (7.6+/-0.7 vs 4.8+/-0.7 ng/ml, P<0.05), insulin (76.2+/-8.9 vs 41.4+/-6.0 pmol/l, P<0.01), and reduced insulin sensitivity (2.43+/-0.2 vs 3.48+/-0.3 min(-1).microU.ml(-1).10(4), P0.5). After correction for total body fat mass, both ncCHF and cCHF were hyperleptinaemic (41.8+/-3.8 and 37.9+/-0.38 vs 24.4+/-2.1 ng/ml/100 g, ANOVA P=0.001). In both patients and controls there was a direct correlation between leptin levels and GHBP (r=0.70 and r=0.71 respectively, both P<0.0001). This relationship was stronger than between GHBP and several parameters of body composition (body mass index (BMI), total and regional body fat mass or % body fat) and held true when sub-groups were tested individually (ncCHF r=0.62, P<0.001; cCHF r=0.79, P<0.0001). In multivariate regression analysis in all CHF patients, serum leptin levels emerged as the strongest predictor of GHBP, independent of age, BMI, total and regional fat mass or % body fat, fasting insulin level and insulin sensitivity. CONCLUSION: Fat mass corrected leptin levels are elevated in CHF patients with and without cachexia. Reduced total fat mass may account for lower leptin levels in cachectic CHF patients compared with non cachectic patients. Leptin strongly predicts GHBP levels in CHF regardless of its hyperleptinaemic state or severely altered body composition as in cardiac cachexia. Leptin could be the signalling link between adipose tissue and GHBP/GH receptor expression in CHF.
- 1 May 2001
- Published by Elsevier in American Heart Journal
- Vol. 141 (5) , 792-799
Uric acid in cachectic and noncachectic patients with chronic heart failure: Relationship to leg vascular resistance
- 1 May 2001
- Published by Elsevier in American Heart Journal
- Vol. 141 (5) , 792-799
Uric acid in cachectic and noncachectic patients with chronic heart failure: Relationship to leg vascular resistance
- 31 December 2000
- Published by Elsevier in International Journal of Cardiology
- Vol. 76 (2) , 122-124
The significance of Leptin in human — do we know it yet?
- 31 December 2000
- Published by Elsevier in International Journal of Cardiology
- Vol. 76 (2) , 122-124
The significance of Leptin in human — do we know it yet?
- 1 December 1999
- Published by Elsevier in International Journal of Cardiology
- Vol. 72 (1) , 1-2
Cytoprotection in acute myocardial
- 1 December 1999
- Published by Elsevier in International Journal of Cardiology
- Vol. 72 (1) , 1-2
Cytoprotection in acute myocardial